• About us
• Contact

Advertisement

Organisation › Details

Roche Venture Fund (RVF)

The Roche Venture Fund is the corporate venture fund of Roche and invests in innovative life science companies. Over the past 20 years, the Roche Venture Fund has invested in over 60 companies globally and currently has a portfolio of around 30 companies located in 10 countries. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally and co-invest with leading venture funds, including other corporate venture funds, on a regular basis. *

 

	Start	2004-10-27 existent
	Group	Roche (Group)
	Industry	venture capital
	Person	Nuechterlein, Carole (Roche 201604 Head of Roche Venture Fund)
	Region	Basel BS
	Country	Switzerland
	Street	124 Grenzacherstr.
	City	4070 Basel BS
		Address record changed: 2023-05-13
Basic data	Employees	n. a.
		* Document for »About Section«: DiogenX SAS. (5/10/23). "Press Release: DiogenX Raises €27.5M Series A Financing to Advance Its First-in-Class Regenerative Treatment for Type 1 Diabetes Towards Clinical Development". Marseille.
		Record changed: 2023-11-16

Advertisement

More documents for Roche (Group)

• [1] Pfizer Inc.. (4/26/24). "Press Release: U.S. FDA Approves Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B". New York, NY....
• [2] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
• [3] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
• [4] PathAI Inc.. (2/13/24). "Press Release: PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics". Boston, MA....
• [5] Repare Therapeutics Inc.. (2/12/24). "Press Release: Repare Therapeutics to Regain Global Rights to Camonsertib". Cambridge, MA & Montréal....
• [6] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
• [7] Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal....
• [8] Roche Deutschland Holding GmbH. (1/10/24). "Press Release: Prof. Hagen Pfundner wird zum 1. Mai 2024 Vorsitzender der Roche Deutschland Holding GmbH"....
• [9] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
• [10] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.